MetaCap

Entera Bio Ltd. (ENTX)

NASDAQ: ENTXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

3.31+0.025 (+0.76%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ENTX stock chart

Technical analysis

Key statistics

All statistics
Market cap
$575.53M
EPS (TTM)
-$0.40
52-week range
0.91 – 4.20
Day range
3.18 – 3.32
Volume / Avg
468.44K / 438.35K
Beta
—

52-week range

$0.91$4.20

ENTX stock today

Shares of Entera Bio (ENTX) finished higher on Nov 20 at $3.31, a gain of 0.76% or $0.025 per share, versus the S&P 500's 3.70% decline. Shares are 21.3% below their 52-week high of $4.20, set on Jul 27, 2026 and 263.2% above the 52-week low of $0.91, in the middle of the past year's range. ENTX is up 70.4% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 30.6%.

Entera Bio has posted a net loss over the last twelve months (EPS of -$0.40), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Entera Bio

Company profile

Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase I clinical trial for the treatment of hypoparathyroidism; EB618, a GLP-1/glucagon dual agonist peptide, which is in Phase I clinical trial for the treatment of obesity, metabolic, and fibrotic disorders; and GLP-2 which is in Phase I clinical trial for the treatment of short bowel syndrome and disorders related to mucosal inflammation and nutrient malabsorption.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Ms. Miranda J. Toledano M.B.A.
Headquarters
Jerusalem
Employees
27
IPO year
2018

Financial highlights

Full financials

In fiscal 2025, Entera Bio generated $42,000 in revenue, down 76.8% from fiscal 2024, its first annual decline since 2023. Entera Bio reported a net loss of $11.4 million, compared with a loss of $9.5 million a year earlier. Gross margin was 0.0% (down from 5.0%) and operating margin -27450.0%.

Entera Bio annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$42.00K$181.00K$0$134.00K$571.00K
Growth-76.80%—-100.00%-76.53%+56.44%
Net income$-11.44M$-9.54M$-8.89M$-13.07M$-12.19M
EPS (diluted)$0.25$0.25$0.31$0.45$0.47

Analyst forecast

Forecast

Consensus (5 analysts)

strong_buy

Avg. price target

$9.75+195.01%

  • Strong buy 0
  • Buy 5
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $9.00High $11.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 13, 2026
EPS actual vs est.
$0.11 vs —

ENTX news

All ENTX news

Entera Bio peers

Health Care sector
ENTX peer companies
CompanyPrice% ChgMarket capCompare
DBVTDBV Technologies S.A. ADR9.02-4.25%$566.82Mvs ENTX
FDMT4D Molecular Therapeutics Inc.10.23-4.57%$576.76Mvs ENTX
CGEMCullinan Therapeutics Inc.8.89-1.98%$577.15Mvs ENTX
SRZNSurrozen Inc.28.46-7.21%$596.40Mvs ENTX
IAMIambic Therapeutics Inc.13.11-8.06%$621.42Mvs ENTX
ETRAElectra Therapeutics Inc.8.11-9.28%$509.85Mvs ENTX
VALNValneva SE ADR5.16-3.82%$490.86Mvs ENTX
DNAGinkgo Bioworks Holdings Inc. Class A7.46-9.02%$483.54Mvs ENTX

Indexes, lists and sector

Entera Bio stock FAQ

What is Entera Bio's stock price today?

ENTX last traded at $3.31 as of Nov 20, 4:00 PM EST, up 0.76% on the day. Prices are delayed at least 15 minutes.

Who is Entera Bio's CEO?

Ms. Miranda J. Toledano M.B.A. is the chief executive officer of Entera Bio Ltd., which has about 27 employees.

What is the ENTX 52-week high?

The 52-week high for ENTX is $4.20 and the 52-week low is $0.91. The stock is currently 21.3% below its high.

Compare ENTX